See more : @Health SA (MLAHC.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Integra LifeSciences Holdings Corporation (IART) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Integra LifeSciences Holdings Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Value HR Co.,Ltd. (6078.T) Income Statement Analysis – Financial Results
- Métropole Télévision S.A. (MMT.PA) Income Statement Analysis – Financial Results
- KlausTech, Inc. (KLTI) Income Statement Analysis – Financial Results
- AmerisourceBergen Corporation (ABC) Income Statement Analysis – Financial Results
- JINHUI LIQUOR Co.,Ltd. (603919.SS) Income Statement Analysis – Financial Results
Integra LifeSciences Holdings Corporation (IART)
About Integra LifeSciences Holdings Corporation
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.54B | 1.56B | 1.54B | 1.37B | 1.52B | 1.47B | 1.19B | 992.08M | 882.73M | 928.31M | 836.21M | 830.87M | 780.08M | 732.07M | 682.49M | 654.60M | 550.46M | 419.30M | 277.94M | 229.83M | 185.60M | 112.63M | 93.44M | 64.99M | 42.50M | 17.50M | 14.70M | 13.10M | 10.20M |
| Cost of Revenue | 653.18M | 587.36M | 597.81M | 520.83M | 564.68M | 571.50M | 435.51M | 349.09M | 326.54M | 352.80M | 334.09M | 314.43M | 299.15M | 268.19M | 244.92M | 252.83M | 214.67M | 168.31M | 105.54M | 87.30M | 70.60M | 45.77M | 36.01M | 26.82M | 21.80M | 6.10M | 5.20M | 4.70M | 3.50M |
| Gross Profit | 888.39M | 970.31M | 944.64M | 851.03M | 952.88M | 900.95M | 752.73M | 642.99M | 556.19M | 575.50M | 502.13M | 516.44M | 480.93M | 463.88M | 437.57M | 401.78M | 335.79M | 250.98M | 172.40M | 142.53M | 115.00M | 66.85M | 57.43M | 38.17M | 20.70M | 11.40M | 9.50M | 8.40M | 6.70M |
| Gross Profit Ratio | 57.63% | 62.29% | 61.24% | 62.03% | 62.79% | 61.19% | 63.35% | 64.81% | 63.01% | 62.00% | 60.05% | 62.16% | 61.65% | 63.37% | 64.11% | 61.38% | 61.00% | 59.86% | 62.03% | 62.02% | 61.96% | 59.36% | 61.46% | 58.74% | 48.71% | 65.14% | 64.63% | 64.12% | 65.69% |
| Research & Development | 174.59M | 101.19M | 93.05M | 77.38M | 79.57M | 78.04M | 63.46M | 58.16M | 50.90M | 51.60M | 52.09M | 51.01M | 51.45M | 48.11M | 44.28M | 60.50M | 30.66M | 25.73M | 11.96M | 14.12M | 12.81M | 8.30M | 7.99M | 7.52M | 8.70M | 8.40M | 6.40M | 6.30M | 5.20M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 592.64M | 616.32M | 637.45M | 594.53M | 687.60M | 690.75M | 624.10M | 455.63M | 415.76M | 445.97M | 394.25M | 373.11M | 358.13M | 305.06M | 281.10M | 281.00M | 225.19M | 157.71M | 98.27M | 99.36M | 59.46M | 40.59M | 32.37M | 43.85M | 22.20M | 15.80M | 20.30M | 9.60M | 6.10M |
| Other Expenses | 69.16M | 13.88M | 16.91M | 27.76M | 27.03M | 8.29M | 1.35M | 845.00K | 4.59M | -763.00K | -1.80M | -721.00K | 16.43M | 12.02M | 14.36M | 12.88M | 12.65M | 8.80M | 6.06M | 4.27M | 3.08M | -3.55M | 2.78M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| Operating Expenses | 836.39M | 731.39M | 747.41M | 699.66M | 794.20M | 789.95M | 707.92M | 527.65M | 476.61M | 509.96M | 459.04M | 442.66M | 426.02M | 365.19M | 339.75M | 354.37M | 268.50M | 192.24M | 116.29M | 117.75M | 75.36M | 45.34M | 43.14M | 56.55M | 33.10M | 25.50M | 28.50M | 17.90M | 12.70M |
| Cost & Expenses | 1.43B | 1.32B | 1.35B | 1.22B | 1.36B | 1.36B | 1.14B | 876.74M | 803.15M | 862.76M | 793.12M | 757.09M | 725.17M | 633.37M | 584.66M | 607.19M | 483.17M | 360.55M | 221.83M | 205.05M | 145.95M | 91.11M | 79.16M | 83.37M | 54.90M | 31.60M | 33.70M | 22.60M | 16.20M |
| Interest Income | 17.20M | 11.92M | 6.74M | 9.30M | 10.78M | 2.80M | 255.00K | 24.00K | 13.00K | 168.00K | 443.00K | 1.21M | 465.00K | 225.00K | 631.00K | 2.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 51.38M | 49.59M | 50.40M | 71.58M | 53.96M | 64.68M | 35.02M | 25.80M | 23.52M | 21.97M | 19.79M | 22.24M | 27.64M | 18.36M | 23.23M | 30.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 123.51M | 121.12M | 123.67M | 118.99M | 114.70M | 115.70M | 88.90M | 72.67M | 9.95M | 12.40M | 47.01M | 18.54M | 16.43M | 39.17M | 39.69M | 33.15M | 27.04M | 21.48M | 13.22M | 11.59M | 9.04M | 7.16M | 6.26M | 5.18M | 2.20M | 1.30M | 1.80M | 2.00M | 1.40M |
| EBITDA | 274.01M | 391.10M | 366.33M | 267.93M | 231.03M | 241.04M | 135.23M | 231.73M | 195.59M | 172.24M | 40.07M | 116.46M | 106.31M | 139.64M | 136.07M | 79.34M | 67.29M | 58.74M | 69.33M | 36.37M | 48.69M | 25.81M | 20.54M | -13.21M | -12.40M | -16.60M | -17.20M | -7.50M | -4.60M |
| EBITDA Ratio | 17.77% | 17.77% | 15.57% | 14.06% | 13.57% | 9.73% | 5.62% | 13.11% | 10.66% | 8.33% | 10.61% | 11.17% | 9.21% | 18.86% | 20.24% | 12.44% | 16.60% | 19.61% | 25.21% | 14.08% | 14.39% | 22.91% | 15.97% | -32.65% | -34.12% | -83.43% | -130.61% | -71.76% | 144.12% |
| Operating Income | 111.53M | 238.92M | 197.23M | 151.37M | 178.98M | 111.00M | 44.80M | 115.34M | 79.59M | 65.54M | -3.64M | 73.78M | 54.91M | 98.69M | 97.82M | 47.41M | 67.29M | 58.74M | 56.11M | 24.78M | 39.65M | 19.19M | 14.29M | -18.38M | -12.40M | -14.10M | -19.00M | -9.50M | -6.00M |
| Operating Income Ratio | 7.23% | 15.34% | 12.79% | 11.03% | 11.79% | 7.54% | 3.77% | 11.63% | 9.02% | 7.06% | -0.44% | 8.88% | 7.04% | 13.48% | 14.33% | 7.24% | 12.22% | 14.01% | 20.19% | 10.78% | 21.36% | 17.04% | 15.29% | -28.29% | -29.18% | -80.57% | -129.25% | -72.52% | -58.82% |
| Total Other Income/Expenses | -30.46M | -25.03M | 17.45M | -57.85M | -33.66M | -53.60M | -33.42M | -24.93M | -18.92M | -24.88M | -21.15M | -21.75M | -26.42M | -16.58M | -24.67M | -16.41M | -7.23M | -10.44M | -1.00M | 3.23M | 3.54M | 3.54M | 1.26M | 7.54M | 7.43M | 5.26M | 2.00M | 1.90M | -19.30M |
| Income Before Tax | 81.07M | 213.89M | 214.68M | 93.52M | 60.10M | 57.40M | 11.39M | 90.41M | 60.67M | 42.98M | -24.79M | 52.03M | 28.49M | 82.11M | 73.15M | 31.01M | 60.06M | 48.31M | 55.10M | 28.01M | 43.19M | 22.73M | 15.54M | -10.85M | -7.80M | -12.30M | -17.00M | -7.60M | -25.30M |
| Income Before Tax Ratio | 5.26% | 13.73% | 13.92% | 6.82% | 3.96% | 3.90% | 0.96% | 9.11% | 6.87% | 4.63% | -2.96% | 6.26% | 3.65% | 11.22% | 10.72% | 4.74% | 10.91% | 11.52% | 19.83% | 12.19% | 23.27% | 20.18% | 16.63% | -16.69% | -18.35% | -70.29% | -115.65% | -58.02% | -248.04% |
| Income Tax Expense | 13.33M | 33.34M | 45.60M | -40.37M | 9.90M | -3.40M | -53.36M | 15.84M | 53.82M | 8.98M | -7.81M | 10.83M | 505.00K | 16.45M | 22.20M | -3.93M | 26.59M | 18.90M | 17.91M | 10.81M | 16.33M | -12.55M | -10.86M | 108.00K | -1.80M | -1.80M | -2.00M | -2.00M | 19.40M |
| Net Income | 67.74M | 180.55M | 169.08M | 133.89M | 50.20M | 60.80M | 64.74M | 74.56M | -3.52M | 34.00M | -16.98M | 41.20M | 27.99M | 65.67M | 50.96M | 34.93M | 33.47M | 29.41M | 37.19M | 17.20M | 26.86M | 35.28M | 26.16M | -11.43M | -6.00M | -12.30M | -17.00M | -7.50M | -25.40M |
| Net Income Ratio | 4.39% | 11.59% | 10.96% | 9.76% | 3.31% | 4.13% | 5.45% | 7.52% | -0.40% | 3.66% | -2.03% | 4.96% | 3.59% | 8.97% | 7.47% | 5.34% | 6.08% | 7.01% | 13.38% | 7.48% | 14.47% | 31.32% | 28.00% | -17.58% | -14.12% | -70.29% | -115.65% | -57.25% | -249.02% |
| EPS | 0.87 | 2.18 | 2.00 | 1.58 | 0.59 | 0.73 | 0.83 | 1.00 | -0.05 | 0.52 | -0.30 | 0.74 | 0.52 | 1.11 | 0.88 | 0.49 | 0.61 | 0.50 | 0.62 | 0.28 | 0.46 | 0.61 | 0.54 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| EPS Diluted | 0.84 | 2.16 | 1.98 | 1.57 | 0.58 | 0.72 | 0.82 | 0.94 | -0.05 | 0.52 | -0.29 | 0.72 | 0.48 | 1.09 | 0.87 | 0.48 | 0.56 | 0.49 | 0.57 | 0.28 | 0.43 | 0.57 | 0.47 | -0.33 | -0.18 | -0.38 | -0.58 | -0.27 | -1.21 |
| Weighted Avg Shares Out | 78.17M | 83.00M | 84.70M | 84.65M | 85.64M | 82.86M | 78.39M | 74.72M | 73.88M | 65.48M | 56.83M | 55.90M | 53.66M | 59.10M | 58.08M | 55.56M | 55.42M | 58.60M | 60.39M | 60.13M | 58.14M | 58.04M | 46.71M | 35.11M | 33.60M | 32.28M | 29.57M | 28.11M | 20.99M |
| Weighted Avg Shares Out (Dil) | 80.34M | 83.52M | 85.49M | 85.23M | 86.49M | 84.45M | 79.12M | 79.19M | 73.88M | 65.92M | 57.60M | 57.03M | 58.99M | 60.30M | 58.58M | 56.76M | 59.16M | 65.49M | 69.13M | 62.20M | 66.21M | 61.79M | 55.59M | 35.11M | 34.12M | 32.28M | 29.57M | 28.11M | 20.99M |
Integra LifeSciences Holdings Corporation (IART) Q1 2024 Earnings Call Transcript
Integra LifeSciences Holdings Corporation [IART] Q1 2024 Earnings Conference Call May 6, 2024 8:30 AM ET Company Participants Jan De Witte - President & CEO Lea Knight - CFO Chris Ward - IR Conference Call Participants Vik Chopra - Wells...
Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Integra LifeSciences Reports First Quarter 2024 Financial Results
PRINCETON, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2024.
Integra LifeSciences to Spotlight CereLink® Intracranial Pressure (ICP) Monitoring System at the American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
PRINCETON, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce that following a successful Q1 2024 U.S. relaunch of its CereLink® ICP Monitoring System, the innovative...
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced that it has rescheduled the release of the Company's first quarter 2024 financial results to Monday, May 6, 2024. In conjunction...
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Retain Integra (IART) Stock Now
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
Integra LifeSciences Completes the Acquisition of Acclarent, Inc.
PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc. , a pioneer in ear, nose and throat (ENT) surgical...
Why Is Integra (IART) Down 4% Since Last Earnings Report?
Integra (IART) reported earnings 30 days ago. What's next for the stock?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Integra Lifesciences Holdings Corp - IART
NEW YORK , March 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating whether the Board of Directors of Integra Lifesciences Holdings Corp (NASDAQ: IART) ("Integra") potentially breached their fiduciary duties to shareholders. Such investors are advised to contact Danielle Peyton...
Source: https://incomestatements.info
Category: Stock Reports